These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36033763)

  • 1. The impact of national centralized drug procurement on health expenditures for lung cancer inpatients: A difference-in-differences analysis in a large tertiary hospital in China.
    Zhang YJ; Ren Y; Zheng Q; Tan J; Yao MH; Huang YX; Zhang X; Zou K; Zhao SY; Sun X
    Front Public Health; 2022; 10():956823. PubMed ID: 36033763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the National Centralized Drug Procurement Policy (4 + 7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series.
    Lan T; Guan L; Pang X; Li X; Yu Q
    J Clin Pharm Ther; 2022 Jan; 47(1):104-111. PubMed ID: 34668203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China.
    Chen L; Yang Y; Luo M; Hu B; Yin S; Mao Z
    Int J Environ Res Public Health; 2020 Dec; 17(24):. PubMed ID: 33334027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of National Centralized Drug Procurement policy on chemical pharmaceutical enterprises' R&D investment: a difference-in-differences analysis in China.
    Li J; Zhang X; Wang R; Cao K; Wan L; Ren X; Ding J; Li W
    Front Public Health; 2024; 12():1402581. PubMed ID: 39011324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National centralized drug procurement and health care expenditure of households-micro-evidence from CFPS.
    Li X; Tao R; Jin Y; Li N
    Front Public Health; 2024; 12():1405197. PubMed ID: 39224556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of China's National Centralized Drug Procurement Policy on pharmaceutical enterprises' financial performance: a quasi-natural experimental study.
    Sun Z; Na X; Chu S
    Front Public Health; 2023; 11():1227102. PubMed ID: 38026347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impacts of national volume-based drug procurement policy on the utilization and costs of antihypertensive drugs in a Chinese medicine hospital: an interrupted time series analysis of 5138 patients.
    Shang L; Cheng Y; Zhou J; Bao Y; Kong D; Huang R; Chen Y; Wang H; Gu N; Ma A
    Front Pharmacol; 2024; 15():1302154. PubMed ID: 38389928
    [No Abstract]   [Full Text] [Related]  

  • 8. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
    Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
    BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare professionals' knowledge, attitude and practice towards National Centralized Drug Procurement policy in central China: A cross-sectional study.
    Huang A; Wang X; Tao Y; Lin L; Cheng H
    Front Pharmacol; 2022; 13():996824. PubMed ID: 36278203
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of China's healthcare price reforms on traditional Chinese medicine public hospitals in Beijing: an interrupted time-series study.
    Zhu D; Shi X; Nicholas S; Bai Q; He P
    BMJ Open; 2019 Aug; 9(8):e029646. PubMed ID: 31401602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact and implications of national centralized drug procurement in China.
    Wang Z; Wang K; Hua Y; Dong X; Zhang L
    Int J Clin Pharm; 2024 Dec; 46(6):1557-1562. PubMed ID: 38990456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of the National Essential Medicines Policy on health expenditures and service delivery in Chinese township health centres: evidence from a longitudinal study.
    Zhang X; Wu Q; Liu G; Li Y; Gao L; Guo B; Fu W; Hao Y; Cui Y; Huang W; Coyte PC
    BMJ Open; 2014 Dec; 4(12):e006471. PubMed ID: 25534214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China.
    Zhao X; Li M; Wang H; Xu X; Wu X; Sun Y; Ning C; Wang B; Chen S; You H; Jia J; Kong Y
    J Clin Transl Hepatol; 2022 Jun; 10(3):420-428. PubMed ID: 35836769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis.
    Wang N; Yang Y; Xu L; Mao Z; Cui D
    BMC Public Health; 2021 Oct; 21(1):1883. PubMed ID: 34663282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impacts of national centralized drug procurement policy on drug utilization of medical institutions: an empirical study in a county-level hospital in China.
    Li H; Lin F; Wang R; Zhu C; Cao K; Chen Y; Fang G; Li J; Ding J; Li W
    BMC Health Serv Res; 2024 Apr; 24(1):513. PubMed ID: 38658940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Did the universal zero-markup drug policy lower healthcare expenditures? Evidence from Changde, China.
    Peng Z; Zhan C; Ma X; Yao H; Chen X; Sha X; Coyte PC
    BMC Health Serv Res; 2021 Nov; 21(1):1205. PubMed ID: 34742310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis.
    Wang X; He X; Zhang P; Zhang M; Ma R; Dai R; Li X
    Int J Equity Health; 2023 Sep; 22(1):200. PubMed ID: 37770924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018-2019: an interrupted time-series analysis.
    Yang Y; Chen L; Ke X; Mao Z; Zheng B
    BMC Health Serv Res; 2021 Jul; 21(1):668. PubMed ID: 34238290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impacts of the national centralized drug procurement policy on the use of policy-related antibiotic agents: the case of Shaanxi province, China.
    Yang C; Ye D; Yan K; Xiang C; Liu S; Gu J; Liu Y; Fang Y
    Expert Rev Anti Infect Ther; 2023 Jun; 21(6):675-684. PubMed ID: 37013799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of National Centralised Drug Procurement policy on the use of policy-related original and generic drugs in China.
    Yang Y; Hu R; Geng X; Mao L; Wen X; Wang Z; Hao S; Cui D; Mao Z
    Int J Health Plann Manage; 2022 May; 37(3):1650-1662. PubMed ID: 35132676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.